Although anti-HER2 monoclonal antibody such as trastuzumab has been proven effective in breast cancer and gastric cancer [1, 2], the clinical trials [3, 4] of lung cancer including patients treated with trastuzumab combined with chemotherapy failed to demonstrate benefit in survival in HER2 IHC positive patients. This evidence concerns the gene ERBB2 and lung cancer.